Le Lézard
Classified in: Health, Science and technology
Subject: Product/Service

Atom Bioscience Enrolling Patients in US as Part of a Global Phase 2b/3 Clinical Trial of a New Investigational Treatment for Chronic Gout


Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.), a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases, has begun enrolling patients in the US for in a Phase 2b/3 clinical trial of ABP-671, a novel investigational orally administered URAT1 inhibitor, for the treatment of chronic gout. Currently 36 sites have been identified in 17 states.

The multicenter, randomized, double-blind trial will enroll 580 patients worldwide. For locations of U.S. trial sites and contacts visit clinicaltrials.gov; (NCT05818085). Part 1 of the trial will evaluate the safety and efficacy of ABP-671 at different doses and regimens compared with either placebo or allopurinol, the current standard of care for management of gout in the U.S. Part 2 of the study will compare dosing regimens of ABP-671 selected from Part 1 with placebo in patients not enrolled in Part 1.

Gout is one of the most common types of inflammatory arthritis. It is caused by long-term hyperuricemia, an excessive concentration of serum uric acid (sUA) greater than 7 mg/dL (420 ?mol/L). Gout seriously affects people's quality of life and can increase the probability of sudden cardiac death. Existing drugs for treating chronic gout have poor efficacy and pose serious safety issues, such as leading to kidney failure, sudden cardiac death, or severe liver toxicity.

About Atom Bioscience

Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co. Ltd.) is a fast-growing innovative drug company, focused on development of best-in-class small molecule therapeutics for treatment of inflammatory and metabolic diseases. The company's lead product, ABP-671, is in clinical development for treatment of chronic gout. Another small molecule ABP-745 has shown significant efficacy and good safety in animal models of anti-inflammation, and is in a phase 1 clinical trial, For more information, please visit: https://www.atombp.com or atombp.us.


These press releases may also interest you

at 19:21
Immersive Wisdom, Inc., provider of a proven TRL-9 distributed communications and ops center software platform for Denied, Degraded, Intermittent, and Limited-Bandwidth (DDIL) environments announced at SOF Week 2024 that it has been awarded a...

at 17:35
Perficient, Inc. ("Perficient" or "the Company"), a leading global digital consultancy transforming the world's largest enterprises and biggest brands, today announced that it has entered into a definitive agreement to be acquired by an affiliate of...

at 17:35
Perficient, Inc. ("Perficient"), the leading global digital consultancy transforming the world's largest enterprises and biggest brands, today reported its financial results for the quarter ended March 31, 2024. Financial Highlights For the...

at 15:32
A report from GDToday:  On the evening of May 3, 2024, the Guangzhou Opera House dazzled audiences with the performance of "Marco Polo," a captivating opera commissioned by the esteemed venue. In order to commemorate the 700th anniversary of the...

at 13:20
Garrett Smith, Founder and CEO of Community Capital Technology Inc. ("Community Capital"), will be attending the Milken Institute Global Conference ("MI Global") May 5-8, 2024 in Los Angeles. The event brings together global executives and...

at 13:16
Quarterhill Inc. ("Quarterhill" or the "Company") , a leading provider of tolling and enforcement solutions in the Intelligent Transportation System ("ITS")...



News published on and distributed by: